Home Social Sciences A Compounding Problem: Pharmaceutical Importation and Drug Production in the United States
Article
Licensed
Unlicensed Requires Authentication

A Compounding Problem: Pharmaceutical Importation and Drug Production in the United States

  • Parker Stallings EMAIL logo
Published/Copyright: December 22, 2023
Become an author with De Gruyter Brill

Abstract

Drug shortages are not a new phenomenon in the United States. Current policies and regulations can be improved to better utilize drug compounding facilities to ensure patient safety, provide practical standards for the interstate market, and focus on patient needs in the marketplace. Adjustments in regulation and incentives such as performance-based bonuses are necessary to encourage registration for 503B outsourcing facilities and address shortages for less profitable drugs. Diversity of drug supply sources is also of the utmost importance to secure the trade of essential medicines in times of drug shortages through a globally diverse supply chain along with a strong system for domestic drug manufacturing and compounding facilities.

Keywords: FDASLA; OECD; JIC; JIT

Corresponding author: Parker Stallings, J. D., Texas Tech University School of Law, Biomedical Sciences, Texas A&M University, Eastland, TX, USA, E-mail:

Received: 2023-12-01
Accepted: 2023-12-01
Published Online: 2023-12-22

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 31.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbbbl-2023-0007/html
Scroll to top button